ClinicalTrials.gg

Program

fezolinetant

Also written as “Fezolinetant”, “fezolinetant - test formulation” and “fezolinetant - reference formulation”.

Its studies are mostly in Hot Flashes · Prostatic Neoplasms · Renal Insufficiency, led by Astellas Pharma.

Furthest: phase 3, since Jun 27, 201921 company-led studies, 3 open or runningNext primary completion: Apr 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma213 open or runningphase 3since Jun 27, 2019Jun 15, 2017Apr 30, 2027phase 1 · NCT07783282

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 5 studies since Jun 15, 2017.

  1. Jan 16, 2020Phase 3 study in Hot FlashesNCT04234204 · 302 enrolled · China, Korea, Republic of, Taiwan
  2. Feb 18, 2020Phase 1 study in Healthy VolunteersNCT04277624 · 22 enrolled · United States
  3. Jun 26, 2020Phase 3 study in Hot FlashesNCT04451226 · 150 enrolled · China
  4. Jul 15, 20202 phase 1 studiesNCT04476849, NCT04482270
  5. Nov 20, 2020Phase 1 study in Healthy SubjectsNCT04641260 · 16 enrolled · United States
  6. Mar 9, 2021Phase 1 study in Healthy VolunteersNCT04793204 · 16 enrolled · China
  7. Sep 1, 2021Phase 2 study in Hot FlashesNCT05034042 · 147 enrolled · Japan
  8. Sep 1, 2021Phase 3 study in Vasomotor SymptomsNCT05033886 · 453 enrolled · Belgium, Canada, Czechia and more
  9. Jun 6, 2022Phase 2 study in Hot FlashesNCT05419908 · 87 enrolled · Belgium
  10. Jan 4, 20242 phase 3 studies in Hot FlashesNCT06206421, NCT06206408
  11. May 29, 2024Phase 3 study in Hot FlashesNCT06440967 · 982 enrolled · Canada, Czechia, Denmark and more
  12. Feb 3, 2025Phase 2 study in Hot FlashesNCT06812754 · 150 enrolled · China
  13. Aug 20, 2026Phase 1 study in Prostatic NeoplasmsNCT07783282 · 56 planned · Bulgaria
  14. Sep 15, 2026Phase 3 study in Hot FlashesNCT07829653 · 100 planned · India

Ahead

  1. Apr 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07783282
  2. Mar 31, 2028Primary completion: phase 3 study in Hot FlashesNCT07829653

TargetBeta

TACR3 →read by rule
“An orally bioavailable, neurokinin/tachykinin 3 receptor (NK1-receptor; NK3R; NK-3R) antagonist, that can be used to treat vasomotor symptoms (VMS) in menopausal woman”NCIt, by rule
“Neurokinin 3 receptor antagonist”ChEMBL 37, by rule

Other programs on TACR3

ProgramCompanyFurthest phaseStudies
elinzanetantruleBayerphase 324
GS1-144ruleChangchun GeneScience Pharmaceuticalphase 26

Studies

All 21 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07829653Hot Flashes · India3RecruitingMar 31, 2028100
NCT07783282Prostatic Neoplasms · Bulgaria1RecruitingApr 30, 202756
NCT06812754Hot Flashes · China2CompletedFeb 11, 2026150
NCT06440967Hot Flashes · Canada, Czechia, Denmark and more3Active, not recruitingJun 25, 2026982
NCT06206421Hot Flashes · Japan3CompletedMar 19, 2026277
NCT06206408Hot Flashes · Japan3CompletedOct 22, 2025410
NCT05419908Hot Flashes · Belgium2CompletedSep 21, 201687
NCT05034042Hot Flashes · Japan2CompletedNov 11, 2022147
NCT05033886Vasomotor Symptoms · Belgium, Canada, Czechia and more3CompletedMar 27, 2023453
NCT04793204Healthy Volunteers · China1CompletedMay 21, 202116
NCT04641260Healthy Subjects · United States1CompletedFeb 12, 202116
NCT04482270Hepatic Impairment · United States1CompletedMar 22, 202126
NCT04476849Renal Insufficiency · United States1CompletedMar 6, 202227
NCT04451226Hot Flashes · China3CompletedJun 13, 2022150
NCT04277624Healthy Volunteers · United States1CompletedFeb 21, 202122
NCT04234204Hot Flashes · China, Korea, Republic of, Taiwan3CompletedApr 20, 2022302
NCT04003389Hot Flashes · United States, Canada, Czechia and more3CompletedJan 4, 20221,831
NCT04003155Hot Flashes · United States, Canada, Czechia and more3CompletedOct 29, 2020527
NCT04003142Hot Flashes · United States, Canada, Czechia and more3CompletedJul 30, 2020501
NCT03436849Healthy Subjects · Japan1CompletedMay 23, 201844
NCT03192176Hot Flashes · United States2CompletedSep 19, 2018356

How it is read

Names in the registry

  • “Fezolinetant”, 12 entries
  • “fezolinetant”, 7 entries
  • “fezolinetant - test formulation”, 1 entry
  • “fezolinetant - reference formulation”, 1 entry
  • “ESN364”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.